Supramolecular Peptide Nanofibrils with Optimized Sequences and Molecular Structures for Efficient Retroviral Transduction by Sieste, S et al.
www.afm-journal.de
© 2021 The Authors. Advanced Functional Materials published by Wiley-VCH GmbH2009382 (1 of 12)
Full PaPer
Supramolecular Peptide Nanofibrils with Optimized 
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Transduction
Stefanie Sieste, Thomas Mack, Edina Lump, Manuel Hayn, Desiree Schütz, 
Annika Röcker, Christoph Meier, Kübra Kaygisiz, Frank Kirchhoff, Tuomas P. J. Knowles, 
Francesco S. Ruggeri,* Christopher V. Synatschke,* Jan Münch,* and Tanja Weil*
Amyloid-like peptide nanofibrils (PNFs) are abundant in nature providing 
rich bioactivities and playing both functional and pathological roles. The 
structural features responsible for their unique bioactivities are, however, 
still elusive. Supramolecular nanostructures are notoriously challenging to 
optimize, as sequence changes affect self-assembly, fibril morphologies, and 
biorecognition. Herein, the first sequence optimization of PNFs, derived 
from the peptide enhancing factor-C (EF-C, QCKIKQIINMWQ), for enhanced 
retroviral gene transduction via a multiparameter and a multiscale approach 
is reported. Retroviral gene transfer is the method of choice for the stable 
delivery of genetic information into cells offering great perspectives for the 
treatment of genetic disorders. Single fibril imaging, zeta potential, vibra-
tional spectroscopy, and quantitative retroviral transduction assays provide 
the structure parameters responsible for PNF assembly, fibrils morphology, 
secondary and quaternary structure, and PNF-virus-cell interactions. Opti-
mized peptide sequences such as the 7-mer, CKFKFQF, have been obtained 
quantitatively forming supramolecular nanofibrils with high intermolecular 
β-sheet content that efficiently bind virions and attach to cellular membranes 
revealing efficient retroviral gene transfer.
DOI: 10.1002/adfm.202009382
1. Introduction
Peptide nanofibrils (PNFs) are ubiquitous 
in nature. They are formed by sponta-
neous self-assembly and exert many vital 
functions in living organisms. Peptide 
nanofibrils consisting of regular cross-β 
sheet structures, often termed amyloid-like 
structures,[1–4] feature many outstanding 
properties such as high rigidity, tensile 
strength, and enhanced resistance towards 
biodegradation.[5,6] They play both func-
tional and pathological roles in many living 
organisms: Serving as templates for mel-
anin biosynthesis,[7] for hormone storage,[8] 
participating in spermatozoa selection and 
clearance,[9] or constituting the fibrillar 
curli structures of Escherichia coli pro-
moting their surface adhesion.[10] Their 
formation has also been associated with 
numerous human diseases (around 50), 
such as Alzheimer’s disease or Diabetes 
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mellitus type 2.[11] We have previously shown that PNF forma-
tion is also common in semen from healthy human individuals 
because semen contains an abundance of amyloidogenic frag-
ments of prostate acidic phosphatase and the semenogelins 1 
and 2.[12,13] PNFs likely play important roles in innate immunity 
and in eliminating poor-quality sperm upon deposition in the 
female reproductive tract.[9] In addition, semen PNFs enhance 
the infectivity of human immunodeficiency virus-1 (HIV-1), her-
pesviruses 1 and 2 and Ebola virus, and may increase the trans-
mission potential of these sexually transmitted pathogens.[14,15]
The rich bioactivity of endogenous amyloids has inspired 
scientists to elucidate structural features crucial for their broad 
functions. Moreover, understanding their specific interactions 
of PNF with cellular membranes and viruses is not only of 
great fundamental interest but also essential to design new 
nanomaterials for medicine, for example, to enhance retro-
viral gene transfer.[16–18] Retroviral gene transfer is the method 
of choice for the delivery of genetic material into cells offering 
great perspectives for the treatment of genetic disorders, malig-
nancies, and infectious diseases.[19,20] Until now, γ-retroviral 
and lentiviral vectors (herein both referred to as retroviral vec-
tors) have been used in more than 478 gene therapy clinical 
trials[21] allowing stable, long-lasting gene expression. HIV-1 
based lentiviral vectors even allow transduction of non-dividing 
cells,[22,23] which is essential to treat, that is, metachromatic leu-
kodystrophy or inherited primary immunodeficiencies with a 
significant clinical benefit.[24,25] However, major challenges in 
retroviral gene delivery need to be overcome such as low trans-
duction efficiencies due to: i) low concentrations of transducing 
particles in the viral vector stock; and ii) low efficiency of 
virion attachment to the target cell. Nowadays, retroviral gene 
delivery is often promoted by a combination of spin-infection 
and utilization of RetroNectin, a long polypeptide, consisting 
of 574 amino acid and a fibronectin derivative that colocalizes 
with virions and cells.[26–29] The large scale use of RetroNectin 
is limited by its high costs and even more importantly, it has 
to be coated onto plates or the inner surface of culture bags 
to capture virions, requiring several washing steps[30–32] which 
impedes in vivo applications.[33]
PNFs have been reported as powerful alternatives to 
RetroNectin as they enhance retroviral gene transfer with a sim-
ilar efficiency but do not require coating.[18,34,35] We discovered 
the self-assembling 12-mer peptide EF-C (QCKIKQIINMWQ) 
corresponding to residues 417–428 of the HIV envelope protein 
gp120 (Figure 1).[18] EF-C PNFs efficiently concentrate virus stock 
solutions and increase cell attachment as well as retroviral gene 
transfer into hematopoietic stem cells and T cells by different 
types of vectors in vitro and ex vivo, which holds various opportu-
nities for gene therapy approaches, in particular chimeric antigen 
receptor T cell (CAR-T) immunotherapy.[18,34–36] Compared to other 
PNFs and known transduction enhancers, EF-C reveals one of the 
highest enhancing effects on retroviral gene transfer and has been 
commercialized under the brand name Protransduzin.[34]
Very little is known about the structural features of bioactive 
PNFs such as EF-C, which severely limits rational approaches 
to further optimize their bioactivity. To the best of our knowl-
edge, no structure–activity study of supramolecular nanofibrils 
has been reported yet. This limitation is due to the fact that 
supramolecular nanostructures are notoriously challenging 
to optimize as multiple parameters affect self-assembly, fibril 
morphologies, and biorecognition and the involved structures 
cover several length scales from the molecular to the meso-
scopic regime. A limited number of studies have investigated 
small sequence variations in amyloid PNFs on transduction 
enhancement.[37–40] However, rational approaches that unravel 
structure–morphology–bioactivity relationships of PNF are still 
elusive. Herein, we report the first sequence optimization of 
PNFs for enhanced retroviral gene transduction via a rational 
multiparameter-based approach. The amino acids and pep-
tide motifs within PNFs responsible for self-assembly, fibrils 
Figure 1. Schematic illustration of the structure–activity study of transduction enhancing PNFs. EF-C is a bioactive fragment of the HIV-1 glycoprotein 
gp120 that forms PNFs and enhances viral transduction. Through multiparameter and multiscale optimization, a library of EF-C derived peptides was 
synthesized. The library was evaluated for fibril formation, structural parameters, virion-PNF-cell interactions, and viral transduction enhancement.
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morphology, secondary and quaternary structure, and virus 
and/or cell binding were identified. We believe that unravelling 
the structural parameters of PNFs responsible for their unique 
bioactivities paves the way to a fundamental understanding of 
the rich bioactivity of PNFs and ultimately addresses the great 
need for improved nanomaterials for clinical applications, for 
example, in gene therapy.
EF-C served as a starting point for multiparameter optimiza-
tion. Its sequence was first divided into smaller fragments to 
identify amino acids and amino acid patterns responsible for 
assembly and interaction with virions or cellular membranes. 
Subsequently, several focused peptide libraries were synthe-
sized as depicted in Figure 2a. EF-C features: i) a short N-ter-
minal QC fragment; ii) an amphiphilic KIKQII domain; and 
iii) a C-terminal NMWQ sequence. The C-terminal NMWQ 
domain represents a fragment of the β20/21 strand in the 
gp120 HIV-1 envelope protein region that has been proposed to 
constitute the primary HIV binding site for the CD4 receptors 
of immune cells[41] and to play a crucial role for the transduc-
tion enhancement of PNFs. The hexameric KIKQII fragment 
features an amphiphilic pattern with three hydrophobic iso-
leucine (I) and two positively charged lysine (K) residues. The 
lipophilic (I) residues could promote self-assembly, whereas the 
hydrophilic and positively charged (K) residues provide solu-
bility for stabilizing the superstructures in aqueous media.[15,17]
PNF formation was achieved by dilution from a dimethyl 
sulfoxide stock solution to PBS buffer and aggregation was con-
firmed by transmission electron microscopy (TEM). Conversion 
rates (CR) from the soluble peptide monomers to supramolec-
ular PNFs were quantified as published previously.[42] ζ-potential 
measurements were performed to determine the charge of 
PNF assemblies; secondary and quaternary structures of PNFs 
were characterized by infrared spectroscopy and intermolecular 
β-sheet structures and were confirmed by the blue-shifted emis-
sion of Proteostat[43] (Figure S1, Table S1, Supporting Informa-
tion). The transduction enhancing properties of the PNFs were 
evaluated in infection experiments using HIV-1 particles as pro-
totype retroviral vectors. Virions were exposed to increasing con-
centrations of PNFs and the mixtures were used to infect TZM-bl 
reporter cells,[44] which are widely used to study HIV infection 
rates. These cells are genetically engineered to express the HIV 
receptors CD4 and CXCR4/CCR5 and contain a stably inte-
grated β-galactosidase gene under the control of the viral long 
terminal repeat promotor region. Upon successful infection, the 
HIV-1 transactivator Tat protein is expressed and turns on the 
viral promotor resulting in β-galactosidase production, which 
Figure 2. PNF library generation upon sequence truncation of EF-C. a) EF-C was subdivided into three domains: i) QC; ii) KIKQII; and iii) NMWQ. 
b) Impact of sequence variations on peptide self-assembly (with + = fibrils and − = no aggregate formation detected), monomer-to-fibril conversion 
rates (CR) and transduction enhancement. Proteostat emission indicates accessible cross β-sheet binding pockets in the fibril core and indicated PNFs 
with + = Proteostat activity and − = no Proteostat fluorescence observed. ζ-potential values for PNF solutions. Average (avg) RLU s−1 in infectivity assay 
for 13–65 µm. c) Representative TEM micrographs of PNF-1 to PNF-5 reveal the formation of fibrillar aggregates. No aggregates were observed for 
PNF-6. The scale bars represent 500 nm. d) HIV-1 infection rates of TZM-bl cells observed in the presence of increasing concentrations of PNF. Shown 
are mean values derived from triplicate infections ± standard deviation. RLU s−1; relative light units per second.
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was quantified in a chemiluminescence-based assay performed 
72 h post infection. None of the peptides tested in this study 
affected cell viability within the concentrations used for transduc-
tion studies (Figure S2, Supporting Information).
2. Results
2.1. PNF Library Generation upon Sequence Truncation
EF-C instantaneously forms positively charged PNFs 
(ζ  =  +17.7  mV) with high conversion rates (CR: 95%) and it 
is used as an internal standard to compare the infectivity 
enhancement of the peptide nanofibrils in different sets of 
experiments, that is, on different days. Several studies have 
shown that even short peptide sequences can exhibit robust 
fibril formation.[45,46] We therefore envisioned the identification 
of EF-C derived peptides with fewer than 13 amino acids that 
retain high transduction enhancement. After deleting the N-ter-
minal glutamine (Q) and stepwise truncation of the C-terminal 
residues, PNF-1 (CKIKQIINMWQ), PNF-2 (CKIKQIINM), and 
PNF-3 (CKIKQII) still formed fibrils but with moderate CRs 
(45–55%) independent of the length of the C-terminal NMWQ 
fragment (Figure 2b,c). The transduction efficiencies of PNF-1 
and PNF-2 with positive ζ-potentials were comparable to EF-C 
(at 65  µM, corresponding to 200  µg mL−1 EF-C, Figure  2d), 
whereas the almost neutral (ζ = + 0.6 mV) PNF-3 without the 
NMWQ fragment was inactive.
After deletion of the (QC) sequence, PNF-4 (KIKQIINMWQ) 
still assembled with high CR (86%) and PNF-5 (KIKQIINM) 
with moderate CR (43%, Figure 2b,c). A time-dependent meas-
urement of the ζ-potential of PNF-4 and PNF-16 over 30 days 
revealed no significant changes in the respective ζ-potential 
values (Figure S3, Supporting Information). Interestingly, 
positively charged PNF-4 and PNF-5, which lack the cysteine 
residue, were considerably less active than PNF-1 and PNF-2 
despite their positive ζ-potentials and comparable CRs. PNF-6 
(KIKQII) did not form fibrils and showed no activity. These data 
gave a first indication that significant transduction enhance-
ment requires: i) PNF formation; ii) positive ζ-potentials; and 
iii) an N-terminal cysteine residue.
2.2. Optimized Amphiphilic Pattern Improves Fibril Formation
In polar solvents, the morphology of intermolecular β-sheet 
rich aggregates is driven by the formation of a bilayer struc-
ture, where hydrophobic domains form the fibril core and the 
hydrophilic side chains arrange at the surface of the fibrillar 
backbone.[18] In order to improve the packing of the peptides 
in the PNFs, we altered: i) the arrangement of the hydrophilic 
and lipophilic amino-acids within the peptide sequences; ii) 
replaced the lipophilic (I) residues by other hydrophobic amino 
acids; and iii) identified minimal sequences with high CRs and 
transduction enhancement.[47,48] The central amphiphilic PNF-6 
(KIKQII) fragment of the EF-C sequence reveals two structural 
defects in its sequence as the second (I) residue of KIKQII 
faces an opposite direction to the other two (I)-residues and the 
polar (Q) is located adjacent to the unpolar (I) and also opposite 
to the polar (K) residues (Figure 3a, blue model). By switching 
the positions of (Q) and its neighboring (I) in the QII frag-
ment to an IQI sequence, a strictly alternating spatial arrange-
ment of hydrophilic and lipophilic residues was obtained 
(Figure  3a, red model). In contrast to the PNF-1-6 series con-
sisting of the KIKQII fragment, PNF-7 (CKIKIQINMWQ), 
PNF-8 (CKIKIQINM), and PNF-9 (CKIKIQI) now provide a 
facial amphiphilic character, where the positively charged and 
nonpolar residues are oriented not only in parallel but also 
perpendicular to the fibril axis. PNF-7 to PNF-9 with positive 
ζ-potentials (ζ = + 10.7–22.3 mV) were formed with moderate to 
high CRs (54–87%) and showed the ability to enhance retroviral 
infection at 65 μm, comparable to EF-C (Figure 3b–d; Figure S4, 
Supporting Information).
The corresponding (C)-free derivatives PNF-10 (KIKIQINMWQ) 
and PNF-11 (KIKIQINM) with the optimized KIKIQI patterns 
also assembled with high CRs (64–93%) into PNFs with positive 
ζ-potentials (ζ  =  + 17.2–41.9  mV) that were however less active 
than EF-C in promoting retroviral infection. Interestingly, PNF-9 
with only seven amino acids assembled into bioactive and posi-
tively charged PNFs (ζ  =  +17.4  mV, CR = 54%), whereas neutral 
PNF-3 (ζ = +0.6 mV) was inactive and PNF-6 and PNF-12 lacking 
the N-terminal (C) did not form fibrils (Figures 2c and 3c). These 
results indicate that the optimized amphiphilic CKIKIQI pattern 
of PNF-9 with N-terminal (C) represents the shortest sequence for 
forming positively charged PNFs displaying transduction enhance-
ment in the range of EF-C.
Next, the (I) residues in PNF-9 were replaced by the less 
bulky and less hydrophobic alanine (A) and the sterically 
more demanding aromatic phenylalanine (F) residues. PNF-13 
(CKAKAQANMWQ), PNF-14 (CKAKAQANM), and PNF-15 
(CKAKAQA) assembled into negatively charged PNFs (ζ = −3.7 
to −9.1  mV) with high (PNF-13, 92%) to moderate CRs (PNF-
14, PNF-15, 38–44%) that did not enhance viral transduction 
(Figure 3b–d). It has been reported that the aggregates of pep-
tides with similar sequences can significantly vary in their 
ζ-potential, often preventing a direct correlation between the 
peptide sequence and ζ-potential.[49–51] The analogous lack in 
enhancing transduction was found after removing the N-ter-
minal (C) of all three alanine derivatives resulting in PNF-S1 
(KAKAQANMWQ), PNF-S2 (KAKAQANM), and PNF-S3 
(KAKAQA) (Figure S5, Supporting Information). In contrast, 
the (F)-containing derivatives PNF-16 (CKFKFQFNMWQ), 
PNF-17 (CKFKFQFNM), and PNF-18 (CKFKFQF) formed 
positively charged PNFs (ζ  =  + 14.1–22.3  mV) with high CRs 
(88–96%) (Figure 3b–d) that all showed significant transduction 
enhancement. Removal of the N-terminal (C) afforded PNF-S4 
(KFKFQFNMWQ) and PNF-S5 (KFKFQFNM) displaying high 
transduction enhancement, whereas PNF-S6 (KFKFQF) was 
inactive (Figure S5, Supporting Information).
2.3. An N-Terminal Cysteine Improves Fibril Formation 
and Enhances Transduction
The impact of the N-terminal accessible thiol-residues was 
furthermore investigated by substitution of (C) in PNF-9 by 
the sulfur-containing amino acid methionine (M) in PNF-S7 
(MKIKIQI). Both PNF-9 and PNF-S7 formed positively charged 
Adv. Funct. Mater. 2021, 31, 2009382
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nanofibrils of comparable morphology as confirmed by TEM 
measurements and both derivatives assembled with similar 
CRs (PNF-9, 54% and PNF-S7, 51%) (Figure S6, Supporting 
Information). However, PNF-S7 was significantly less bioac-
tive than PNF-9 at all tested concentrations. The substitu-
tion of (C) by (M) in the shortest bioactive sequence PNF-18 
afforded PNF-S8 (MKFKFQF), which was inactive (Figure S6, 
Supporting Information). The cysteine groups in the bioac-
tive peptides could in principle undergo oxidation reactions 
under air, which could enhance the formation of disulfide 
bridges.[52] Therefore, we have studied bioactivity of PNF-8 in 
the presence of the reducing agent TCEP. Our data shows that 
the application of TCEP has no significant influence on bioac-
tivity (Figure S7, Supporting Information). We conclude that in 
our study, N-terminal (C) leads to robust fibril formation and 
enhances infectivity also in case of short peptide sequences.
2.4. Unraveling the Structure–Activity Relationship
We have shown that the formation of bioactive PNFs required 
moderate to high CR as well as an overall positive ζ-potential. 
However, PNFs with similar positive charges and CRs, such 
as PNF-2 and PNF-5 could still reveal significantly different 
transduction enhancing activities (Figures  2 and  3). There-
fore, CR and positive ζ-potential represent critical features, but 
additional, yet unknown parameters exist that account for the 
observed variability in the biological activity of PNFs. To identify 
these parameters, we first correlated the sequence and transduc-
tion enhancement of PNFs with their secondary and quaternary 
structure that was obtained by FTIR spectroscopy (Figure 4) 
from freeze-dried PNF solutions. It has been shown that the 
properties of amyloid structures in a liquid and dried environ-
ment remain highly conserved.[53–55] In proteins, the IR spectra 
Figure 3. Improving PNF aggregating and transduction enhancement. a) Optimization of the amphiphilic fragment (II) of EF-C. Hydrophilic amino 
acids are given in grey and hydrophobic in color. b) Tabular summary of the features of PNF-7 to PNF-18 including PNF formation as observed in TEM 
measurements with + = fibrils and − = no aggregate formation detected. Monomer-to-fibril conversion rates (CR) were determined in a fluorescence-
based assay. Proteostat emission indicates accessible cross β-sheet binding pockets in the fibril core and was assessed for PNFs with + = Proteostat 
activity and − = no Proteostat fluorescence observed. ζ-potential values for PNF solutions. Average (avg) RLU s−1 in infectivity assay for 13–65 µm. 
c) Representative TEM micrographs of PNF-8,-9,-15,-17,-18 reveal fibrillar aggregate morphologies. No aggregates were observed for PNF-12. Scale bars: 
500 nm. d) Transduction enhancement assay showing HIV-1 infection rates of TZM-bl cells observed in the presence of increasing concentrations of 
PNF given as mean values from triplicate infections ± standard deviation. RLU s−1; relative light units per second.
Adv. Funct. Mater. 2021, 31, 2009382
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Figure 4. FTIR secondary structure evaluation and infectivity enhancement as a function of intermolecular β-sheet for all PNFs. FTIR spectra of 
a) positively and b) negatively charged PNFs. c) Modification of the amide band I upon intrinsic switch. d) Method of quantification of intramolecular 
native versus intermolecular aggregated β-sheet structure. Secondary structure versus e) average infection enhancing activity and f) average infection 
enhancing activity normalized by charge and conversion rate. g) Linear fit of activity versus intermolecular β-sheet for the groups of peptides with 
chemical similarity. Full length: PNF-1,-7,-16; C cut: PNF-4,-10,-S4; C and WQ cut: PNF-5,-11,-S5; WQ cut: PNF-2,-8,-17; NMWQ cut: PNF-3,-9,-18,-S7,-S8.
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are dominated by the amide band I, whose shape is intimately 
related to the secondary and quaternary structure of the pro-
tein backbone. A first qualitative view of the spectra shows that 
the amide band I of almost all PNFs exhibited a maximum 
in the range between 1615–1630 cm−1 (Figure  4a,b). The high 
absorption in this spectroscopic range demonstrates the pres-
ence of a high content of intermolecular β-sheet structures, 
stabilized by a tight network of hydrogen bonds, similar to amy-
loidogenic aggregates.[56–58] Then, the integration of the decon-
volved amide band I by a second derivative analysis allowed 
robust quantification of each structural contribution (α-helix, 
random coil, native and aggregated β-sheet) (Figure 4c,d).[59,60] 
The percentage of native intramolecular secondary structural 
elements (1635–1700 cm−1) was quantified and correlated versus 
the percentage of intermolecular hydrogen bonded β-sheet 
(1610–1635 cm−1) for each PNF (Figure 4d).
The PNF library showed a wide variation of secondary struc-
tures as indicated by the heterogeneity of shapes of the amide 
band I of the PNFs (Figure 4a,b). The amide I band of the dif-
ferent negatively charged PNFs varied significantly (Figure 4b), 
and with similar standard deviation to the one of the positive 
PNFs (Figure 4a). However, there were no major differences in 
the secondary and quaternary structures of negatively charged 
PNFs that would explain the observed significant differences 
in their transduction enhancement compared to positively 
charged PNFs and the EF-C sequence. This observation is in 
line with previous reports indicating that the ζ-potential of 
the PNFs is the first factor determining their transduction 
enhancing features.[17,18,61] However, positively charged PNFs 
revealed high variations in their structure and ability to boost 
transduction. An initial qualitative investigation of the spectra 
of these PNFs indicated that sequence modifications altered 
their secondary and quaternary structure, which also had an 
impact on their transduction enhancing features. For instance, 
the intrinsic switch of the core (Q) and (I) of PNF-3 (CKIKQII) 
leads to the formation of PNF-9 (CKIKIQI) with a higher 
content of intermolecular β-sheet structures that displayed 
improved transduction enhancing features (Figure  4c,d). The 
corresponding spectra showed that both in the presence and 
absence of the N-terminal cysteine (C), the intrinsic switch 
KIKQII → KIKIQI allowed us to modulate with a higher 
degree of freedom the secondary structure of the PNFs upon 
the stepwise removal of WQ and NM amino acids (Figure S8, 
Supporting Information).
2.5. The Intermolecular β-Sheet Content of PNFs Modulates 
their Transduction Efficiency
Next, we assessed how the molecular structure of the posi-
tively charged PNFs affects their impact on transduction effi-
ciency. To reduce the intrinsic variability in the biological 
assay, the average transduction enhancement was calculated 
(Table S2, Supporting Information) and plotted as average bio-
logical activity against the content of the measured intermo-
lecular β-sheet structures (Figure  4e). These data showed an 
unexpected and significant correlation as the biological activity 
increased steadily as a function of the intermolecular β-sheet 
content of the PNFs. As both charges and the CR are important 
parameters contributing to transduction enhancement, we 
normalized our results against CR and ζ-potential. Normaliza-
tion for CR considers only the fraction of peptide monomers 
participating in PNF formation, whereas normalization for 
charge recognizes that only positively charged PNFs facilitate 
virus transport into cells (Figure  4f; Figure S9, Supporting 
Information). Interestingly, even after CR and charge normali-
zation, a direct correlation between infectivity enhancement 
and the presence of intermolecular β-sheet content of the PNFs 
was observed.
To unravel the functional relationship between secondary 
structure and bioactivity, we also considered that the side chain 
absorption of the amino acids W, Q, and N can significantly 
contribute to the amide band I of a short peptide (≈5–15%). 
Thus, we grouped the peptides into three groups that are 
either chemically identical, that is, in case of structural iso-
mers, or consist of amino acids, whose side chains do not affect 
the amide band I absorption. The plot of the β-sheet content 
versus infectivity for each of these groups revealed that these 
physical quantities are correlated by a statistically significant 
linear relationship (Figure 4g, R = 0.92–0.98). These data clearly 
demonstrate that the content of the intermolecular β-sheet 
structures in the PNFs is a fundamental parameter modulating 
their infectivity (Figure 4g).
We observed above that (C) promotes enhanced transduction 
rates (Figure 2). The structural analysis revealed that deletion of 
C-terminal cysteine leads to a net average reduction of the inter-
molecular β-sheets content (≈15%) in the PNFs (Figure 4g, light 
blue PNF-4,-10,-S4 versus green PNF-1,-7,-16). Interestingly, the 
influence of the N-terminal (C) is not of a hydrophobic nature, 
as an exchange of (C) with the chemically similar (M) decreased 
the intermolecular β-sheets content and reduced infectivity in 
the corresponding peptides libraries (Figure  4g, red PNF-9, 
18 to PNF-S7/-S8). Therefore, we found that the main role of 
the N-terminal (C) is to generate amyloid-like PNFs with a 
higher content of hydrogen bonded β-sheets and thus more 
stable PNFs with a higher degree of order,[45,62] which obviously 
enhances their infectivity.
Deletion of both the N-terminal (C) and the C-terminus 
had an impact on the content of intermolecular β-sheet, 
which also affected transduction. We observed that the 
N-terminal (C) or part of the C-terminus (NMWQ) is a nec-
essary prerequisite for high infectivity of the EF-C sequence. 
Truncation of the C-terminal (WQ) sequence only slightly 
affected PNF infectivity (Figure  4f, green versus blue), and 
this minor difference in secondary structure was attributed 
to the absorption of the (WQ) side chains that were removed 
in the corresponding series PNF-2,-5,-8,-17,-S5. The removal 
of both (C) and C-terminal (WQ) sequence slightly reduced 
the intermolecular β-sheet content (≈5%), which also dimin-
ished infectivity enhancement (Figure  4g, blue PNF-4,-10,-S4 
versus violet PNF-1,-7,-16), whereas deletion of (C) and the full 
C-terminus significantly reduced the intermolecular β-sheet 
content (≈20%), which resulted in an almost complete loss of 
the transduction enhancing features (Figure S10, Supporting 
Information).
As mentioned previously, the optimization of the amphiph-
ilic pattern also resulted in significant changes in the secondary 
structure (Figure 4c,d). This effect was smaller for the sequences 
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close in length to EF-C and it became more pronounced for the 
highly truncated sequences, that is, those lacking the NMWQ 
fragment (Figure 4g, red). In these (C)-containing peptides, the 
intrinsic switch enabled the modulation of the secondary struc-
ture and their transduction enhancing features (Figure 4g, red). 
By optimizing the internal amphiphilic pattern of PNF-3, which 
afforded PNF-9, both β-sheet content and transduction effi-
ciency received a significant boost (Figure 4g), which is in good 
agreement with an optimized packing of the molecules due 
to the elimination of a polarity “defect” in the structure. The 
effects delivered by the intrinsic switch were of similar impor-
tance, when considering the (F)-derivative peptides (PNF-18). 
This structure–activity relationship represents the first result 
clearly indicating that the molecular structure, and in particular 
the content of intermolecular β-sheet content, is a fundamental 
parameter determining the infectivity enhancing properties of 
peptide nanofibrils.
2.6. Negatively Charged PNFs Bind Virions but Not Cells
The positively charged (K) residues could be involved in inter-
actions with negatively charged viral membranes and/or the 
negatively charged lipid bilayers of cellular membranes. In this 
way, positively charged PNFs could enhance virus transduction 
by reducing the electrostatic repulsion forces between viral and 
cellular membranes.[15,17] In order to elucidate the interaction 
partner of PNFs, negatively charged peptide sequences based 
on bioactive PNF-7 to PNF-9 were prepared in which the hydro-
philic, polar (K) residue was replaced by glutamic acid (E). The 
corresponding derivatives PNF-19 (CEIEIQINMWQ), PNF-20 
(CEIEIQINM), and PNF-21 (CEIEIQI) formed PNFs with nega-
tive zeta potentials with good CRs (43–79%), almost comparable 
to their corresponding positive (K)-derivatives PNF-7 to PNF-9. 
The CR of the negative (E)-peptides PNF-19 to PNF-21, but their 
biological activity was an order of magnitude smaller (Figure 5).
Figure 5. Variation of PNF charge from positive (bioactive) to negative (inactive). Both (K)-and (E)-rich fibrils bind virions, but the latter did not 
increase infectivity. a) Substitution of positively charged Lysine (K) residues by negatively charged glutamic acid (E) in the peptide sequences (PNF-7 to 
PNF-9) yielded corresponding negatively charged derivatives (PNF-19 to PNF-21) to elucidate the impact of PNF charge on self-assembly and infectivity 
enhancement. b) Tabular list of peptide derivatives PNF-19 to PNF-21 with glutamic acid residues and a positively charged lysine derivative set PNF-7 
to PNF-9 including the ability to form PNFs as observed in TEM measurements with + = fibrils detected. Monomer-to-fibril conversion rates (CR) were 
determined in a fluorescence-based assay. High values indicate a large percentage of peptides participating in fibril formation. Proteostat emission 
indicates accessible cross β-sheet binding pockets in the fibril core and was assessed for PNFs with + = Proteostat activity and − = no Proteostat fluo-
rescence observed. ζ-potential values for PNF solutions confirm the negative charge of fibrillar aggregates with glutamic acid residues. c) Infectivity 
assay showing HIV-1 infection rates of TZM-bl cells observed in the presence of increasing concentrations of PNF. Values above the columns depict the 
change from baseline (0 µm). Shown are mean values derived from triplicate infections ± standard deviation. RLU s−1; relative light units per second. 
d) Representative TEM micrographs of PNF-19 to PNF-21 reveal fibrillar aggregate morphologies. The scale bars represent 500 nm. e) Representative 
LSM micrographs of Proteostat-labelled PNFs (red) incubated with YFP-labelled viral particles (green) revealed formation of mesoscale virus-PNF 
clusters for PNF-7 and PNF-19. f) Representative LSM micrographs of Proteostat-labelled PNFs (red) and TZM-bl cells (nucleus in blue). PNFs were 
added to cells for 30 min and analyzed. After 1 h, cells were washed and again analyzed. PNF-7 revealed association with cellular membranes while 
PNF-19 did not associate with cells. The scale bars represent 100 µm.
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Next, we studied the formation of mesoscale virus-PNF clus-
ters by applying fluorescent laser scanning microscopy (LSM). 
PNFs were stained by the red-emitting fluorophore Proteostat 
and yellow fluorescent protein (YFP)-labelled retroviral parti-
cles (green) were used. Colocalization of PNFs and virions was 
observed for all investigated PNFs as depicted in Figure 5e and 
Figure S11, Supporting Information, indicating that despite 
their negative charge, PNF-19 and PNF-21 were still able to bind 
virions, although to a lower extent as their positively charged 
analogues. The interaction of PNFs with cellular membranes 
was then assessed by incubating Proteostat-labelled PNFs 
with TZM-bl cells for 30 min. The samples were analyzed by 
confocal microscopy before washing confirming the presence 
of PNF. After 1 h, cells were washed with PBS and examined 
again. PNF clusters were removed that did not significantly 
interact with the cellular surface. In contrast to (K)-containing 
PNFs, negatively charged PNFs based on optimized peptide 
sequences interacted with virions but they did not associate 
with the cellular membrane (Figure S12, Supporting Informa-
tion), which most likely explains their lack of activity in the 
transduction assay (Figure 5c). The (K) residues in the bioactive 
PNFs reveal enhanced virus binding and facilitate colocalization 
of the virus-PNF complexes at cellular membranes. Interest-
ingly, a set of peptides PNF-S9 and PNF-S10, where the charged 
residues were replaced with serine (S) (Figure S13, Supporting 
Information), show intermediate activity roughly between that 
of the highly active (K)-containing PNFs and the non-active 
(E)-containing PNFs. Colocalization of these PNFs and viral 
particles indicated poor attachment to cellular membranes 
confirming the overall importance of positively charged resi-
dues to enhance viral transduction efficacy. We conclude that 
a positive ζ-potential is crucial for the transduction enhancing 
properties of PNFs but it is not essential for PNF assembly and 
interaction with virions.
2.7. The Shortest Transduction Enhancing Sequence PNF-18 
is a Potent Enhancer of Lenti- and γ-Retroviral Transduction
The peptide PNF-18 is a highly efficient transduction enhancer 
providing a short sequence of only seven amino acids. We 
selected this hit peptide for a comparative analysis with 
the EF-C 12-mer using multiple viral vectors and cell lines 
(Figure 6a). A lentiviral vector encoding a luciferase gene and 
carrying the G-protein of the vesicular stomatitis virus (VSV-G), 
a viral fusion protein often used in gene transfer approaches, 
was generated. p24 antigen of the viral pseudotype prepara-
tion (2 or 14 ng) were exposed to EF-C and PNF-18, and used 
to inoculate HEK 293T cells. Transduction efficiencies were 
determined 3 days later by quantifying luciferase activities in 
cellular lysates. Both PNFs substantially increased transduc-
tion (Figure  6b). At 100  µg mL−1, PNF-18 is more active than 
EF-C, with maximal transduction enhancement of 32-fold 
(2 ng p24) and 17× (14 ng p24), as compared to 23× (2 ng p24) 
and 10× (14 ng p24), respectively, for EF-C. We also generated 
a lentiviral vector, SEW LUC2, by co-transfection of a crippled 
lentiviral genome encoding luciferase, a gag-pol and a VSV-G 
expression plasmid. The resulting vector was treated with EF-C 
and PNF-18, and mixtures were added to HeLA (TZM-bl) cells 
and murine fibroblast 3T3 cells. Again, transduction rates were 
determined by quantifying luciferase 3 days later. As shown in 
Figure  6c, both PNF dose-dependently increased transduction 
of both cell lines analyzed. PNF-18 revealed maximal enhance-
ment of 121-fold in TZM-bl cells and 66-fold in 3T3 cells. 
Since one of the most advanced clinical applications of PNF 
is to increase retroviral transduction of T cells in CAR T cell 
therapy,[34,63] we finally evaluated PNF-18 in this setting. For this, 
a GFP encoding retroviral vector carrying the Env protein of the 
Gibbon ape leukemia virus (GALV-Env) which is commonly 
used in CAR T cell therapy was generated, without applying 
any optimization protocols or virion concentration by ultracen-
trifugation. Next, the vector was exposed to PNF-18 and added 
to primary T cells isolated from two independent blood donors. 
Transduction rates were analyzed 3 days later by determining 
the percentage of GFP + cells by flow cytometry (Figure 6d,e). 
In the absence of PNFs, hardly any transduced GFP+ cells were 
detected. However, with an increasing concentration of PNF-18, 
the number of transduced cells gradually increased to 9.5% for 
donor A, and 7.2% for donor B (Figure  6d), corresponding to 
63 or 48-fold increased transduction rates as compared to the 
control containing no PNFs (Figure  6e). These results show, 
that fibrils derived from the 7-mer peptide PNF-18 substantially 
improved lentiviral gene transfer rates into adherent and pri-
mary suspension cells, independently of the viral fusion protein 
and the vector types used, rendering PNF-18 as a novel highly 
versatile and easy to produce transduction enhancer.
3. Conclusions
Supramolecular nanostructures are notoriously challenging to 
optimize as rational approaches face multiparameter and mul-
tiscale challenges. Herein, we have reported the first sequence 
optimization of peptides forming bioactive amyloid-like PNFs 
that enhance retroviral gene transduction based on single fibril 
analysis and quantitative infection data. The impact of different 
amino acid patterns and sequences responsible for assembly, 
fibril morphologies, virus and cell membrane binding were 
resolved. We found that the motif NMWQ in QCKIKQIINMWQ 
was not essential for their transduction enhancing properties. 
Optimizing the amphiphilic six amino acid sequence (KIKQII) 
afforded (CKFKFQF) with quantitative peptide-to-fibril CRs. 
The N-terminal (C) also affected fibril morphology by further 
increasing the intermolecular β-sheet content, which also con-
tributed to high transduction efficacy in particular in short 
sequences. The structure–activity relationship showed a linear 
correlation of the content of intermolecular β-sheet structures 
and transduction enhancement of the PNFs. The (K)-residues 
were found important for binding both virions and cell sur-
face structures by reducing the electrostatic repulsion forces 
between viral and cellular membranes to colocalize virions 
at the cellular membrane, which is required for transduction 
enhancement. Interestingly, negatively charged PNFs with opti-
mized sequence patterns could still bind virions but the formed 
negative PNF-virion complexes did not co-localize with cellular 
membranes.
The nine-mers PNF-8 and PNF-17 as well as the seven-
mer PNF-18 (CKFKFQF) represent a minimum sequence 
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combining PNF formation with high CRs and high infectivity 
due to: 1) high content of cross-β-sheet structures; 2) ability to 
bind virions; and 3) interact with cellular membranes. PNF-18 
provides a more than 40% reduced sequence length compared 
to the original 12-mer EF-C sequence promoting optimized 
lentiviral HIV infection and enhanced retroviral transduction 
with high efficiency outperforming the original EF-C sequence. 
PNF-18 is less expensive to synthesize, it can be purified and 
Figure 6. Fibrils derived from the shortened peptide PNF-18 are potent enhancer of lenti- and γ-retroviral transduction. a) Structure of PNF-18 and the 
parental EF-C peptide. b) Transduction efficiencies of a low (left) or median (right) dose of VSV-G pseudotyped HIV-1 NL4-3 particles encoding a lucif-
erase. Viral particles were exposed to the indicated concentrations of EF-C and PNF-18 and used to inoculate HEK 293T cells. Luciferase activities were 
determined three days later, shown are mean values derived from triplicate infection ± standard deviation (SD). c) Transduction efficiencies of a VSV-G 
pseudotyped lentiviral vector (SEW LUC2) in TZM-bl or 3T3 cells. The SEW LUC2 vector preparation was incubated with the PNF and used to infect 
TZM-bl and 3T3 cells. Luciferases activities were determined 3 days later, shown are mean values derived from triplicate infections ± SD. d) Dot plots 
showing GFP+ CD4 T cells obtained from two independent donors after transduction with GALV pseudotyped γ-retrovirus at indicated concentrations 
of PNF-18 at three days post transduction. e) Percentage of GFP positive cells shown in (d). Numbers above data points give the n-fold enhancement 
of transduction as compared to controls containing no PNF.
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produced without batch-to-batch variations and it further 
provides reactive thiol groups to introduce further chemical 
modifications, that is, via maleimide chemistry. We envision 
that negatively charged (E)-based PNFs capable of binding viral 
particles without interacting with cellular membranes could 
offer exciting opportunities to develop antiviral nanomaterials 
as well as PNFs targeting specific cell types as positive charges 
usually mediate unspecific electrostatic interactions with 
cellular membranes.
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